697 related articles for article (PubMed ID: 22677034)
1. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
2. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
[TBL] [Abstract][Full Text] [Related]
3. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
4. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
5. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
6. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
[TBL] [Abstract][Full Text] [Related]
7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
9. Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms.
Ballanger B; Beaudoin-Gobert M; Neumane S; Epinat J; Metereau E; Duperrier S; Broussolle E; Thobois S; Bonnefoi F; Tourvielle C; Lavenne F; Costes N; Lebars D; Zimmer L; Sgambato-Faure V; Tremblay L
J Neurosci; 2016 Feb; 36(5):1577-89. PubMed ID: 26843639
[TBL] [Abstract][Full Text] [Related]
10. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
[TBL] [Abstract][Full Text] [Related]
11. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease.
Jiménez-Sánchez L; Blesa J; Del Rey NL; Monje MHG; Obeso JA; Cavada C
Neuropharmacology; 2020 Jun; 170():107806. PubMed ID: 31589886
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
14. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
18. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
Rothblat DS; Schroeder JA; Schneider JS
J Neurosci Res; 2001 Aug; 65(3):254-66. PubMed ID: 11494360
[TBL] [Abstract][Full Text] [Related]
20. Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
Molinet-Dronda F; Blesa J; Del Rey NL; Juri C; Collantes M; Pineda-Pardo JA; Trigo-Damas I; Iglesias E; Hernández LF; Rodríguez-Rojas R; Gago B; Ecay M; Prieto E; García-Cabezas MÁ; Cavada C; Rodríguez-Oroz MC; Peñuelas I; Obeso JA
Neurobiol Dis; 2022 Jun; 167():105669. PubMed ID: 35219857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
